171 related articles for article (PubMed ID: 32782529)
1. Effect of
Chuang SC; Huang CW; Chen YT; Ma CJ; Tsai HL; Chang TK; Su WC; Hsu WH; Kuo CH; Wang JY
Oncol Lett; 2020 Sep; 20(3):2119-2130. PubMed ID: 32782529
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to
Li CC; Chang TK; Chen YC; Tsai HL; Huang CW; Su WC; Ma CJ; Yin TC; Chen PJ; Wang JY
Cancer Manag Res; 2022; 14():1541-1549. PubMed ID: 35498511
[TBL] [Abstract][Full Text] [Related]
3. Characteristic differences between patients who have undergone surgical treatment for lung metastasis or hepatic metastasis from colorectal cancer.
Iwasaki A; Shirakusa T; Yamashita Y; Noritomi T; Maekawa T; Hamada T
Thorac Cardiovasc Surg; 2005 Dec; 53(6):358-64. PubMed ID: 16311973
[TBL] [Abstract][Full Text] [Related]
4. Genetic differences between lung metastases and liver metastases from left-sided microsatellite stable colorectal cancer: next generation sequencing and clinical implications.
Wang Z; Zheng X; Wang X; Chen Y; Li Z; Yu J; Yang W; Mao B; Zhang H; Li J; Shen L
Ann Transl Med; 2021 Jun; 9(12):967. PubMed ID: 34277767
[TBL] [Abstract][Full Text] [Related]
5. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?
Passot G; Kim BJ; Glehen O; Mehran RJ; Kopetz SE; Goere D; Overman MJ; Pocard M; Marchal F; Conrad C; Aloia TA; Vauthey JN; Chun YS;
Ann Surg Oncol; 2018 Jan; 25(1):179-187. PubMed ID: 29071660
[TBL] [Abstract][Full Text] [Related]
6. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research.
He K; Wang Y; Zhong Y; Pan X; Si L; Lu J
Onco Targets Ther; 2020; 13():12601-12613. PubMed ID: 33335401
[TBL] [Abstract][Full Text] [Related]
7. Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.
Cercek A; Braghiroli MI; Chou JF; Hechtman JF; Kemeny N; Saltz L; Capanu M; Yaeger R
Clin Cancer Res; 2017 Aug; 23(16):4753-4760. PubMed ID: 28446505
[No Abstract] [Full Text] [Related]
8. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
9. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
[TBL] [Abstract][Full Text] [Related]
10. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
Yaeger R; Cowell E; Chou JF; Gewirtz AN; Borsu L; Vakiani E; Solit DB; Rosen N; Capanu M; Ladanyi M; Kemeny N
Cancer; 2015 Apr; 121(8):1195-203. PubMed ID: 25491172
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Geredeli C; Yasar N
World J Surg Oncol; 2018 Mar; 16(1):67. PubMed ID: 29587749
[TBL] [Abstract][Full Text] [Related]
12. Impact of somatic mutations on patterns of metastasis in colorectal cancer.
Lipsyc M; Yaeger R
J Gastrointest Oncol; 2015 Dec; 6(6):645-9. PubMed ID: 26697197
[TBL] [Abstract][Full Text] [Related]
13. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
[TBL] [Abstract][Full Text] [Related]
14. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
16. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis.
Garde Noguera J; Jantus-Lewintre E; Gil-Raga M; Evgenyeva E; Maciá Escalante S; Llombart-Cussac A; Camps Herrero C
Mol Clin Oncol; 2017 Mar; 6(3):403-408. PubMed ID: 28451421
[TBL] [Abstract][Full Text] [Related]
17. Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis.
Ottaiano A; Normanno N; Facchini S; Cassata A; Nappi A; Romano C; Silvestro L; De Stefano A; Rachiglio AM; Roma C; Maiello MR; Scala S; Delrio P; Tatangelo F; Di Mauro A; Botti G; Avallone A; Nasti G
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708575
[TBL] [Abstract][Full Text] [Related]
18. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
19. An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients.
Liang L; Tian J; Yu Y; Wang Z; Peng K; Liu R; Wang Y; Xu X; Li H; Zhuang R; Cui Y; Zhu C; Liu T
Cell Physiol Biochem; 2018; 50(2):768-782. PubMed ID: 30308491
[TBL] [Abstract][Full Text] [Related]
20. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
Osumi H; Shinozaki E; Suenaga M; Matsusaka S; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Mise Y; Ishizawa T; Inoue Y; Takahashi Y; Saiura A; Uehara H; Mun M; Okumura S; Mizunuma N; Miki Y; Yamaguchi T
Int J Cancer; 2016 Aug; 139(4):803-11. PubMed ID: 27004837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
